LDL hemoperfusion-A new procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with human whole blood

Artificial Organs

Volumn 21, Issue 9, 1997, Pages 977-982

  Bosch, T ^a,e   Schmidt, B ^a   Kleophas, W ^b   Gillen, C ^c   Otto, V ^c   Passlick Deetjen, J ^c   Gurland, H J ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Fresenius AG ^*  (Germany)

^c FRESENIUS AG   (Germany)

^d Kuratorium für Dialyse Kidney Center   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

DALI; Hemoperfusion; Low density lipoprotein apheresis; Low density lipoprotein cholesterol Lipoprotein(a)

Indexed keywords

ADSORPTION; CHOLESTEROL; DISEASES; LIPOPROTEINS; PATIENT TREATMENT;

ADSORBERS; CLINICAL APPLICATION; DALI; HEMOPERFUSION; LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN APHERESIS; LOW-DENSITY LIPOPROTEIN CHOLESTEROL-LIPOPROTEIN(A); WHOLE BLOOD;

BLOOD;

ACID CITRATE DEXTROSE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYACRYLAMIDE GEL;

ADULT; AGED; APHERESIS; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; EXTRACORPOREAL CIRCULATION; FEMALE; HEMOPERFUSION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030768347     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1997.tb00511.x     Document Type: Article

References (12)

1. Bosch T. State of the art of lipid apheresis. Artif Organs 1996;20:292-5.
2. Bosch T, Seidel D, Gurland HJ. Efficacy of lipid apheresis: Definitions and influencing factors. Int J Artif Organs 1995;18:210-5.
3. Thompson GR. Progression and regression of coronary artery disease. Curr Opin Lipidol 1992;3:263-7.
4. Bosch T. Lipidapherese: Indikation-Methodik-Differentialtherapie. Nieren Hochdruckkr 1992;21:89-102.
5. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17:640-52.
6. Kirschbaum B. Comparison of indirect methods to estimate plasma volume changes during hemodialysis. Int J Artif Organs 1989;12:307-13.
7. Lupien PJ, Moorjani S, Lou M, Brun D, Gagne C. Removal of cholesterol from blood by affinity binding to heparin-agarose: Evaluation of treatment in homozygous familial hypercholesterolemia. Ped Res 1980;14:113-7.
8. Kuroda T, Okamoto T, Yokoyama T, Yamawaki N, Inagaki K, Umegae M, Yokoyama S, Yamamoto A. High-capacity low-density lipoprotein adsorbent for plasmapheresis. In: Oda T, Shiokawa Y, Inoue N, eds. Proceedings of the First International Congress of the World Apheresis Association: Therapeutic Plasmapheresis (VI). Cleveland: ISAO Press, 1987:556-9.
9. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoprotein by precipitation at low pH: First clinical application of the HELP system. Klin Wochenschr 1987;65:161-168.
10. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-35.
11. Pokrovsky SN, Sussekov AV, Adamova IY, Afanasieva OI, Benevolenskaya GF, Konovalov GA, Kukharchuk VV. Development of immunosorbents for apo B-containing lipoprotein apheresis. Artif Organs 1995;500-5.
12. Schulf-Werner P, Schütz E, Seyde WC, Eisenhauer T, Janning G, Armstrong VW, Seidel D. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation. Eur J Clin Invest 1989;19:30-7.